Prospects for vaccine protection against HIV-1 infection and AIDS

Annual Review of Immunology

Volumn 20, Issue , 2002, Pages 73-99

  Letvin, Norman L ^a   Barouch, Dan H ^a   Montefiori, David C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GENE PRODUCT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLASMID DNA; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; GENE DELETION; GENE MUTATION; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; PRIMATES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0036221435     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.20.081501.094854     Document Type: Review

References (148)

1. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1
2. Pathogenic diversity of simian immunodeficiency viruses
3. Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques
4. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins
5. Persistent infection of macaques with simian-human immunodeficiency viruses
6. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV)
7. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
8. + lymphocytes can control HIV infection in vitro by suppressing virus replication
9. HIV-specific cytotoxic T lymphocytes in seropositive individuals
10. AIDS virus-specific cytotoxic T lymphocytes in lung disorders
11. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
12. + cytolytic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
13. + T cells with a predominant Vβ usage during the primary immune response to HIV
14. + lymphocyte response in acutely infected rhesus monkeys
15. T cell receptor Vβ repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus
16. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
17. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
18. Phenotypic analysis of antigen-specific T lymphocytes
19. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection
20. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
21. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
22. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
23. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
24. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys
25. + lymphocytes
26. + T cell depletion in simian immunodeficiency virus-infected macaques
27. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
28. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection
29. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
30. Control of a mucosal challenge and prevention of clinical AIDS in rhesus monkeys by a multiprotein DNA/MVA vaccine
31. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination
32. Comparative studies of severla HIV vaccine approaches
33. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
34. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
35. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS
36. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
37. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi
38. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition
39. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
40. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children
41. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
42. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
43. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viremia
44. Simian immunodeficiency virus evades a dominant epitope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I
45. Escape of human immunodeficiency virus from immune control
46. Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
47. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
48. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
49. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
50. + T cells produce antiviral cytokines but are impaired in cytolytic function
51. Skewed maturation of memory HIV-specific CD8 T lymphocytes
52. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
53. Viral immune evasion due to persistence of activated T cells without effector function
54. Cellular immune responses to HIV
55. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
56. + T cell responses associated with control of viremia
57. Immune control of HIV-1 after treatment of acute infection
58. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
59. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
60. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge
61. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
62. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
63. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
64. The role of the humoral immune response in HIV infection
65. Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype
66. Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes
67. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype
68. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein
69. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12
70. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization
71. A role for carbohydrates in immune evasion in AIDS
72. Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo
73. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term non-progressive infection
74. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
75. The antiviral activity of antibodies in vitro and in vivo
76. Delineation of a region of the human immunodeficiency virus gp120 glycoprotein critical for interaction with the CD4 receptor
77. Energetics of the HIV gp120-CD4 binding reaction
78. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
79. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
80. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: Soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120
81. HIV entry and tropism: The chemokine receptor connection
82. A new classification for HIV-1
83. Atomic structure of the ectodomain from HIV-1 gp41
84. Core structure of gp41 from the HIV envelope glycoprotein
85. HIV entry and its inhibition
86. Mechanism of human immunodeficiency virus type 1 (HIV-1) neutralization: Irreversible inactivation of infectivity by anti-HIV-1 antibody
87. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization
88. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
89. The antigenic structure of the HIV gp120 envelope glycoprotein
90. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
91. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
92. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates
93. A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1
94. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgGlb12
95. Crystal structure of neutralizing human IgG against HIV-1: A template for vaccine design
96. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1
97. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
98. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
99. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence
100. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
101. Live attenuated, multiple deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
102. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients
103. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1
104. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1
105. A formalin-inactivated whole SIV vaccine confers protection in macaques
106. Anti-cell antibody in macaques
107. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: Long-term follow-up
108. 6/L CD4 cell counts: A randomized control trial
109. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
110. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
111. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
112. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees
113. + cytotoxic T lymphocytes
114. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
115. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
116. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
117. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
118. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
119. + cytotoxic T lymphocyte responses in seronegative volunteers
120. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
121. Development of a preventive vaccine for Ebola virus infection in primates
122. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
123. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
124. Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses
125. DNA vaccines
126. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
127. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
128. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intramolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
129. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution
130. HIV-1 antibody - Debris or virion?
131. Refocusing neutralizing antibody responses by targeted dampening of an immunodominant epitope
132. Neutralizing antibody induction in a simian-human immunodeficiency virus (SHIV) primate model: Lack of original antigenic sin
133. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
134. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex
135. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera
136. Rapid induction of HIV-1 immune responses by canarypox (ALVAC) HIV-1 and gp120 SF2 recombinant vaccines in uninfected volunteers
137. Recombinant modified vaccinia virus Ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques
138. + T lymphocytes
139. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
140. Control of SIV rebound through structured treatment interruptions during early infection
141. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
142. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermitent antiretroviral therapy in chronic HIV type 1 infection
143. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques
144. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
145. + T-cell in humans without foreign helper epitopes
146. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
147. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
148. Viral load and heterosexual transmission of human immunodeficiency virus type 1